JAK1 and atopic eczema: Oclacitinib, while effectively managing itching and inflammation in dogs with allergic dermatitis through targeting the JAK1 pathway and inhibiting cytokines associated with inflammation, may also inadvertently alter the delicate balance of immune regulation.